Literature DB >> 22241291

Liver regeneration after portal vein embolization using absorbable and permanent embolization materials in a rabbit model.

Jacomina W van den Esschert1, Krijn P van Lienden, Lindy K Alles, Albert C van Wijk, Michal Heger, Joris J Roelofs, Thomas M van Gulik.   

Abstract

OBJECTIVE: To compare the safety and hypertrophy response after portal vein embolization (PVE) using 2 absorbable and 3 permanent embolization materials.
BACKGROUND: Portal vein embolization is used to increase future remnant liver volume preoperatively. Application of temporary, absorbable embolization materials could be advantageous in some situations, provided sufficient hypertrophy is achieved from the nonembolized lobe.
METHODS: Six groups of rabbits (n = 5) underwent PVE of 80% of the total liver volume using saline (sham), gelatin sponge, fibrin glue, polyvinyl alcohol particles with coils, n-butyl cyanoacrylate, or polidocanol. The rabbits were killed after 7 days. Portography, computed tomographic volumetry, Doppler ultrasonography, laboratory liver function and damage parameters (nonembolized) liver-to-body weight ratio, immunohistochemistry, and cytokine and growth factor tissue levels were assessed to examine the differences in the liver regeneration response.
RESULTS: Polidocanol was discontinued because of toxic reactions in 3 rabbits. Gelatin sponge was the only material that was absorbed after 7 days and resulted in less hypertrophy of the nonembolized lobe than the other 3 materials. There were no significant differences in hypertrophy response between the other 3 embolization groups. Volumetric data obtained from computed tomography were supported by liver-to-body weight ratio and the amount of proliferating hepatocytes. The volume gain of the nonembolized lobe was proportional to the volume loss of the embolized liver lobes. The number of Kupffer cells in the embolized liver lobe was significantly higher in the fibrin glue, polyvinyl alcohol particles with coils, and n-butyl cyanoacrylate groups than in the sham and gelatin sponge groups. However, the levels of interleukin-6, tumor necrosis factor-α, hepatocyte growth factor, and transforming growth factor-β1 were significantly lower.
CONCLUSIONS: Temporary occlusion using gelatin sponge for PVE resulted in significantly less hypertrophy response than the use of permanent embolization materials. Except for polidocanol, none of the embolization materials exhibited evident hepatotoxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22241291     DOI: 10.1097/SLA.0b013e31823e7587

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  9 in total

1.  Chronological changes in the liver after temporary partial portal venous occlusion.

Authors:  Koji Hamasaki; Susumu Eguchi; Akihiko Soyama; Masaaki Hidaka; Mitsuhisa Takatsuki; Fumihiko Fujita; Kengo Kanetaka; Shigeki Minami; Tamotsu Kuroki
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

2.  Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique.

Authors:  Boris Guiu; Patrick Chevallier; Alban Denys; Elisabeth Delhom; Marie-Ange Pierredon-Foulongne; Philippe Rouanet; Jean-Michel Fabre; François Quenet; Astrid Herrero; Fabrizio Panaro; Guillaume Baudin; Jeanne Ramos
Journal:  Eur Radiol       Date:  2016-04-18       Impact factor: 5.315

3.  Relationship of immunonutritional factor with changes in liver volume after portal vein embolization.

Authors:  Atsushi Nanashima; Yukinori Tanoue; Koichi Yano; Masahide Hiyoshi; Naoya Imamura; Takeomi Hamada; Kengo Kai; Eiji Kitamura; Yasuto Suzuki; Kousei Tahira; Fumiya Kawano; Takeshi Nagayasu
Journal:  Surg Open Sci       Date:  2022-05-28

4.  Evaluating surgeon attitudes towards the safety and efficacy of portal vein occlusion and associating liver partition and portal vein ligation: a report of the MALINSA survey.

Authors:  Ryan W Day; Claudius Conrad; Jean-Nicolas Vauthey; Thomas A Aloia
Journal:  HPB (Oxford)       Date:  2015-08-10       Impact factor: 3.647

5.  Accurate quantitation of Ki67-positive proliferating hepatocytes in rabbit liver by a multicolor immunohistochemical (IHC) approach analyzed with automated tissue and cell segmentation software.

Authors:  Chris M van der Loos; Onno J de Boer; Claire Mackaaij; Lisette T Hoekstra; Thomas M van Gulik; Joanne Verheij
Journal:  J Histochem Cytochem       Date:  2012-09-01       Impact factor: 2.479

6.  Liver related complications in unresectable disease after portal vein embolization.

Authors:  Floor Huisman; Kasia P Cieslak; Krijn P van Lienden; Roelof J Bennink; Thomas M van Gulik
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

Review 7.  Portal Vein Embolization as an Oncosurgical Strategy Prior to Major Hepatic Resection: Anatomic, Surgical, and Technical Considerations.

Authors:  Sonia T Orcutt; Katsuhiro Kobayashi; Mark Sultenfuss; Brian S Hailey; Anthony Sparks; Bighnesh Satpathy; Daniel A Anaya
Journal:  Front Surg       Date:  2016-03-11

8.  Safety and outcomes of pre-operative portal vein embolization using N-butyl cyanoacrylate (Glue) in hepatobiliary malignancies: A single center retrospective analysis.

Authors:  Amar Mukund; Aniket Mondal; Yashwant Patidar; Senthil Kumar
Journal:  Indian J Radiol Imaging       Date:  2019 Jan-Mar

Review 9.  Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive-a Laboratory and Clinical Perspective.

Authors:  William D Spotnitz
Journal:  ISRN Surg       Date:  2014-03-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.